A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystit… (NCT05740007) | Clinical Trial Compass
TerminatedPhase 2
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Stopped: Business decision
United States98 participantsStarted 2023-03-28
Plain-language summary
The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort). Subjects will be assigned to receive either the study drug or placebo by chance.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed with IC/BPS by a urologist or other clinician specializing in IC/BPS
* Chronic bladder pain associated with filling the bladder over the past 6 months
* Compliant with eDiary completion and meets weekly average daily score for bladder pain at its worst during the pretreatment period
* Has at least 1 of the following urinary symptoms over the past 6 months: nocturia ≥2 voids/night, daytime frequency \>8×day, urgency
* Body mass index (BMI) ≤40 kg/m2
* Willing to use a rectally administered product once daily for 12 weeks
Exclusion Criteria:
* Male subject has history of bacterial prostatitis or benign prostatic hyperplasia with active symptoms that are difficult to distinguish from IC/BPS
* Has a condition that can be a contraindication to using a rectal foam
* Has cancer under active treatment or a history of uterine, cervical, pelvic, colorectal, ovarian, or vaginal cancer
* Has a history of benign or malignant bladder tumors
* Has an active urinary tract infection or had ≥2 UTIs within the past 90 days
* Has an uncontrolled major psychiatric condition or has made a suicide attempt during the past 2 years
* Has a malabsorption syndrome
* Had surgery in the pelvic or abdominal region within the past 90 days or is planning pelvic or abdominal region surgical procedures before the end of the study
* Has received a cystoscopy with or without hydrodistension for diagnostic purposes (ie, not for pain relief) within the past 30 days or a cystoscop…
What they're measuring
1
Change from baseline (CFB) in weekly average of daily bladder pain (which can include sensations like burning, pressure, and/or discomfort) at its worst at Week 12